We are live on ! Find out more

60 Degrees Pharmaceuticals

SXTP

Market cap $4.4M

1.25 USD

+0.08

6.84%

At close Updated Sep 28, 4:00 PM EDT

Pre-market

After hours

1.27

+0.02

1.6%

1 day

6.84%

5 days

30.21%

1 month

21.36%

3 months

-29.78%

6 months

-17.22%

Year to date

-39.32%

1 year

-79.71%

5 years

-99.89%

10 years

-99.89%

About: 60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.

Employees: 3

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference

60 Degrees Pharma (Nasdaq: SXTP) will present on demand at H.C. Wainwright beginning Sept. 11 and hold 1 x 1 investor meetings Sept. 14–16 in New York.

60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today its financial results for the second quarter of 2026, ended June 30, 2026. Financial Highlights for the Quarter Ended June 30, 2026: Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand for the second quarter of 2025.

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules

WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 574,713 shares of its common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 574,713 shares of common stock and short-term series B warrants to purchase up to 574,713 shares of common stock at a purchase price of $1.74 per share (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $1.49 per share and will be exercisable upon issuance.

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026

Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis ( NCT06207370 ). The outcome of the interim analysis will be disclosed no later than October 6, 2026.

60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026

60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases

60 Degrees Pharma (Nasdaq: SXTP) secures exclusive option to develop castanospermine for tick-borne diseases, expanding its infectious disease pipeline.

60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases

60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the independent Data Safety Monitoring Board has recommended continuation of the B-Free chronic babesiosis study ( NCT06656351 ), following a review of safety data from the first six patients from baseline through Day 30. The B-Free study is evaluating recovery from fatigue following treatment with the ARAKODA® regimen of tafenoquine (loading dose of 200 mg per day for four days, then 200 mg weekly through Day 90) in patients with severe persistent fatigue and laboratory evidence of exposure to Babesia spp.

60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

License allows the Company to commence large-scale extraction of castanospermine from the seeds of Castanospermum australe Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company's recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S. WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida State University to commence large-scale production techniques to extract and purify castanospermine from the seeds of Castanospermum australe (commonly known as the Australian Chestnut, the Moreton Bay Chestnut, and the Black Bean Tree) for non-prescription uses. Castanospermine is the principal component of Australian Chestnut Extract.

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones Minimum enrollment to support interim analysis expected as soon as early July 2026 Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of tafenoquine in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S. WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled in the randomized, double-blind, placebo-controlled clinical trial ( NCT06207370 ) to evaluate the efficacy and safety of tafenoquine in treating babesiosis in humans. The study, which will enroll at least 24 patients prior to an interim analysis, is being conducted at five clinical sites in the Northeastern United States.

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026, ended March 31, 2026. Financial Highlights for the Quarter Ended March 31, 2026: Net product revenues decreased approximately 1% from $164 thousand for the first quarter of 2025 to approximately $162 thousand for the first quarter of 2026.

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

Zacks Investment Research

60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know

60 Degrees Pharmaceuticals Inc. (SXTP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know

See News Rankings

Price charts implemented using Lightweight Charts™